Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial Elmwood Park, New Jersey, July 06, 2026 – Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch1 of Olanzapine for Injection, 10 mg/vial, Single -Dose Vial. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa®2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. According to IQVIA® sales data for the 12 -month period ending May 2026, the Zyprexa® IntraMuscular Injection market3 achieved annual sales of approximately $25.4 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and afford able treatment options to meet the evolving needs of patients and healthcare providers.” 1Glenmark’s Olanzapine for Injection, 10 mg/vial, Single-Dose Vial is only approved for the indication(s) listed in Glenmark’s approved label. 2All brand names and trademarks are the property of their respective owners. 3Market includes brand and all available therapeutic equivalents. Note: IQVIA ® data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for and will only be marketed for the indications listed in Glenmark’s approved label, which may be different than the approved RLD indications. *IQVIA® National Sales Perspectives: Retail & Non-Retail, May 2026 About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research ‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. W ith 11 world -class manufacturing facilities across four continents, supported by six cutting -edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health product s, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact India United States Akhila Natarajan | [email protected] | +91 22 4018 9999 Adfactors PR | [email protected] | +91 9819514233 Akhila Natarajan | [email protected] Danielle Hagen | [email protected] 202-365-6112

The release as fetched from its publisher. glenmarkpharma.com ↗